Alumis updates LUMUS Phase 2 trial timeline on ClinicalTrials.gov

ALUMIS INC.

Revised primary completion and study completion dates for LUMUS trial (ESK-001 in SLE) posted November 22, 2024.
LUMUS is a global, randomized, double-blind, placebo-controlled Phase 2 trial.
Company states the revisions conform with prior SEC filings and public guidance.
No specific new dates or financial impact disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.